Display Settings:

Format

Send to:

Choose Destination
Semin Oncol. 2011 Oct;38(5):613-20. doi: 10.1053/j.seminoncol.2011.04.013.

Molecular biology of myelodysplastic syndromes.

Author information

  • 1Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.

Abstract

Myelodysplastic syndromes (MDS) are a group of clonal hematopoetic disorders marked by ineffective hematopoiesis, peripheral cytopenias, and an increased risk of transformation to acute myeloid leukemia. Multiple processes govern hematopoietic progenitor proliferation and natural differentiation into mature myeloid elements. Molecular events that disrupt any of these processes have the potential to lead to ineffective hematopoiesis and an MDS phenotype. Recent advances in genomic analysis have identified a number of new genes that may be involved. The molecular description of MDS will lead to better understanding, classification, and treatment of this disease.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
21943667
[PubMed - indexed for MEDLINE]
PMCID:
PMC3183432
Free PMC Article

Images from this publication.See all images (1)Free text

Figure
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk